Replies to post #100242 on Biotech Values

[DewDiligence]

ITMN—They also seem to be talking about converting to the royalty [as opposed to profit- and cost-sharing] option with Roche. I think that would be a good idea for them (actually anything to get their burn down) but then some may have a hard time justifying their current market cap with less upside.

I interpret this as an indication that ITMN itself questions the value of the ITMN-191 program. Why spend more money on a program with a checkered past and a bleak future? Instead, they could use the money to in-license a new compound.